If the share price goes up then they'll need fewer shares for the incentive plan.
That's what bothers me about the almost 100 million shares of the plan. They will only need that many to make their 10's of millions of dollars if the share price languishes in the single digits until 2029. If that's the case then they don't need big incentives anyway. So fewer shares set aside for the incentive plan means more confidence in a higher share price.
I understand that trials for cancer, NASH, alzheimer's, etc... will take time and we'll need expert help that can get stock as compensation but going by past actions the lion's share will go to Nader, Kelly and the board. And they don't need that huge pool to draw from if the share price stays low. Plus we need assurance that those trials will be paid for by the extra 100M shares recently authorized and there won't be the need to authorize more.